Release date: 2017-04-21 Identifying specific genetic mutations in non-small cell lung cancer patients (NSCLC) can help clinicians choose the best treatment option. The Journal of Molecular Diagnostics describes a new blood test that quickly and accurately identifies genetic mutations associated with non-small cell lung cancer, enabling clinicians to make early, personalized treatment options. Dr. Gary A. Pestano, vice president of development and operations at Biodesix, one of the inventors of the method, said the study was crucial because it proved for the first time that it can be detected by blood in the absence of a hospital diagnostic device. Actionable mutations, and it takes only 72 hours from collecting samples to generating results. The suability mutation plays an important role in the occurrence and development of tumors. Treatments that target mutations can improve outcomes, such as reducing the risk of death or reducing the severity of the disease. For non-small cell lung cancer, certain genetic mutations can be used to identify whether a patient is sensitive or resistant to a therapy. For example, epidermal growth factor receptor (EGFR) mutations may sensitize patients to EGFR tyrosine kinase inhibitor drugs (such as erlotinib or gefitinib), while patients with EGFR T790M mutations are more resistant to these drugs. Subject to some. Patients with ALK rearrangements are not sensitive to EGFR tyrosine kinase inhibitor drugs, but are sensitive to other targeted therapies, such as ceretinib. Dr. Pestano said, "The new technology we developed can detect suspicious mutations in patients with early stage non-small cell lung cancer, thereby increasing clinical outcomes." The new technology uses a highly sensitive gene mutation detection method based on the separation of DNA into droplets to detect specific circulating tumor DNA mutations and RNA mutations in the blood. The researchers tested in 1600 samples. Of these samples, 10.5% had EGFR sensitivity, 18.8% had EGFR resistance, 13.2% had KRAS mutations, and 2% had EML4-ALK mutations. The study found that this method has a sensitivity of more than 80% and a specificity of 100% for each mutation. In most cases, blood tests and tissue biopsies yield the same results. Another advantage of this approach is that it can be performed quickly: 94% of the available results are available after 72 hours of blood draw, and tissue-based testing can take several weeks to get results. In addition to providing insights into treatment, this approach may also help to assess disease recurrence, drug resistance, and the like. The first author of this article, Dr. Hestia Mellert, said that this approach allows doctors in remote areas to access patient information more quickly. Reference materials: New blood test offers potential for faster, targeted treatment of non-small-cell lung cancer Source: Bio-Exploration Brand computer chips, dual-frequency integrated circuits, cross-magnetic induction detection, bringing higher accuracy, reliability and stability. 2. Automatic control system, using special magnetic materials and unique technology, the detection accuracy of the probe is particularly high, and the accurate position of the broken needle is displayed in 8 detection areas. 3. Dual probe design, double detection function, higher safety performance, compared with other types of needle detectors, at the same detection height, the sensitivity is increased by 10%. 4. Automatic detection, automatic induction, automatic stop when no detection is needed, 0-10 sensitivity adjustment, when there is a broken needle, the conveyor belt automatically stops and returns backwards. 5. With a counting function, it can count the number of qualified or unqualified products. 6. It has two alarm modes: sound effect and light alarm. 7. Luxurious appearance, novel style, time-saving and power-saving, simple operation Rapid PCR detection,Rapid Detection Rapid Detection PCR Kit Viral Antigen Detection Jiangsu iiLO Biotechnology Co., Ltd. , https://www.iilogene.com